Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Regen BioPharma (RGBP) over the last 12 years, with Q4 2025 value amounting to -$197941.0.

  • Regen BioPharma's Free Cash Flow fell 19819.82% to -$197941.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$515153.0, marking a year-over-year increase of 2142.01%. This contributed to the annual value of -$383591.0 for FY2025, which is 4895.91% up from last year.
  • Latest data reveals that Regen BioPharma reported Free Cash Flow of -$197941.0 as of Q4 2025, which was down 19819.82% from -$160005.0 recorded in Q3 2025.
  • In the past 5 years, Regen BioPharma's Free Cash Flow ranged from a high of -$10463.0 in Q4 2022 and a low of -$1.1 million during Q3 2021
  • Its 5-year average for Free Cash Flow is -$170781.3, with a median of -$118818.0 in 2022.
  • As far as peak fluctuations go, Regen BioPharma's Free Cash Flow skyrocketed by 9625.16% in 2022, and later plummeted by 145152.44% in 2023.
  • Quarter analysis of 5 years shows Regen BioPharma's Free Cash Flow stood at -$279135.0 in 2021, then surged by 96.25% to -$10463.0 in 2022, then plummeted by 1451.52% to -$162336.0 in 2023, then surged by 59.11% to -$66379.0 in 2024, then tumbled by 198.2% to -$197941.0 in 2025.
  • Its Free Cash Flow was -$197941.0 in Q4 2025, compared to -$160005.0 in Q3 2025 and -$55977.0 in Q2 2025.